

1 **Cell strain-derived induced pluripotent stem cell as a genetically controlled**
2 **approach to investigating aging mechanisms and viral pathogenesis**

3
4 Amanda Makha Bifani¹, Hwee Cheng Tan¹, Milly M Choy¹, Eng Eong Ooi^{1,2,3,*}

5 ¹Programme in Emerging Infectious Diseases, Duke-NUS Medical School,
6 Singapore

7 ²Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS
8 Academic Medical Centre, Singapore

9 ³Saw Swee Hock School of Public Health, National University of Singapore,
10 Singapore

11 *Correspondence: engeong.ooi@duke-nus.edu.sg

12

13 **ABSTRACT**

14 The expansion of the geographic footprint of dengue viruses (DENVs) and their
15 mosquito vectors have affected more than half of the global population, including
16 older adults who appear to show elevated risk of severe dengue. Despite this
17 epidemiological trend, how age and senescence impact virus-host interactions
18 involved in dengue pathogenesis to increase the risk of severe dengue is poorly
19 understood. Herein, we show that conversion of diploid cells with finite lifespan into
20 iPSCs followed by differentiation back into cell strain can be an approach to derive
21 genetically identical cells at different stages of senescence to study virus and aging
22 host interactions. Our findings show that cellular senescence impact the host
23 response to infection and the ensuing outcome. We suggest iPSC-derive cell strains
24 as a potentially useful technical approach to genetically controlled host-virus
25 interaction studies to understand how aging impact viral pathogenesis.

26

27

28 INTRODUCTION

29 Dengue is the most common mosquito-borne viral disease globally (1). This acute
30 disease, which when severe can be life-threatening, is caused by four genetically
31 distinct dengue viruses (DENVs) (DENV1,-2,-3 and -4), all of which belong to
32 *Flavivirus* genus. An estimated 390 million infections occur annually (2) and
33 populations throughout the tropics face frequent and recurrent dengue epidemics.
34 More are expected to be affected as the geographic footprint of the *Aedes*
35 mosquitoes that transmit DENV expand from the tropical to the subtropical regions of
36 the world (3).

37 When frequent and recurrent dengue epidemics first emerged in Southeast Asia
38 after the Second World War, dengue was primarily a paediatric disease (4, 5). Early-
39 life exposure to DENV remains enriched in children in certain parts of the region,
40 leading to immunity by early adulthood (5). However, changes in the urban
41 population demographics as well as vector distribution have led to a shift in the
42 burden of dengue to include adults and even the elderly (6-10). Dengue in older
43 adults present public health challenges as these individuals appear to experience
44 greater morbidity and mortality rates (11). Epidemiological observations have found
45 increased rates of hospital and intensive care admissions (11), length of
46 hospitalisation (12), and risk of severe dengue (12-15). Although age is associated
47 with increased prevalence of co-morbidities, such as cardiovascular diseases and
48 diabetes that also complicate dengue (16, 17), age alone has also been shown to be
49 a risk factor for severe dengue (12). This age-related increased risk of severe
50 disease extends beyond dengue. Vaccination with the live attenuated yellow fever
51 vaccine (YF17D) in those above 60 years of age has, despite the attenuated nature
52 of YF17D, has been associated with severe viscerotropic infection and disease (18,
53 19).

54 Despite the increased risk of poor clinical outcome in older adults, how aging affects
55 the pathogenesis of DENV infection and severe adverse events following YF17D
56 vaccination has remained undefined. A major limitation is the lack of suitable *in vitro*
57 tools. Cell lines that are commonly used in virus-host interaction studies are immortal
58 and do not age. Cell strains, or diploid cells with finite lifespan, do age (20).
59 However, most of these cell strains were developed decades ago and are thus

60 mostly close to the end of their finite lifespan. Moreover, global stocks of several of
61 these cell strains are approaching depletion (21). Cell strains at a spectrum of
62 chronological ages are thus not readily available for virus and aging host interaction
63 studies.

64

65 Herein, we explored the use of induced pluripotent stem cells (iPSCs) generated
66 from senescent diploid cells, and then differentiated from iPSCs back into senescent
67 cells as a resource for age-dependent viral pathogenesis investigations; conversion
68 of diploid cells to iPSCs serve as a renewable resource for differentiation and
69 passaging into genetically identical cells at different stages of senescence. We show
70 that early passages of differentiated cells display markers of differentiation while later
71 passage cells exhibit cellular senescence. The difference in passage number
72 influences the flavivirus infection phenotype, potentially offering an *in vitro* system to
73 study host immune response to infection in the context of cellular senescence.

74

75 RESULTS

76

77 **Senescent cell strains can be reprogrammed into induced pluripotent stem**

78 **cells.** Cell strains, WI-38 and MRC-5 were created as cancer free, virus free cells for
79 vaccine production (20, 22). These diploid cell strains, however, have since proven
80 useful for *in vitro* cell biology and basic virology studies as they are not immortalised
81 (23, 24). We reprogrammed these cell strains into iPSCs using non-modified of
82 Yamanaka factors (Klf4, Oct4, Sox2 and c-Myc) as well as the transcription factors
83 Nanog and Lin28 (25) rather than conventional dedifferentiating techniques such as
84 retro- or lentivirus vectors that alter the host cell genome (Figure 1). Fourteen days
85 post-transfection with the cocktail of reprogramming mRNA, three suspected iPSC
86 colonies were isolated from WI-38 (W1-3) and 6 colonies from MRC-5 cells (M1-6).

87

88 *Figure 1. Senescent cell strains WI-38 and MRC-5 can be reprogrammed to iPSCs.*
89 *(A-B) Karyogram of WI-38 derived iPSC colony W1 (a) and of MRC-5 derived iPSC*
90 *colony M3 (b) (GTG-banded cells analysed, n=20. Karyograms made, n=5). (C)*
91 *Immunofluorescence assay employing anti-Tra-1-60 (1/500), anti-oct4 (1/250) and*
92 *nuclear stain DAPI (1/10000) in parent WI-38 and MRC-5 fibroblasts as well as W1*
93 *and M3 iPSCs at 10X magnification. (D-E) Quantitative PCR of fibroblast associated*
94 *genes and iPSC marker genes in parental cell strains and de-differentiated iPSCs.*
95 *Statistical analysis was performed using students t-test (each dot represents 1*
96 *experiment, n=3 biological replicates/experiment, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,*
97 *****p ≤ 0.0001).*

98

99 To verify that a diploid genome was maintained through reprogramming from
100 senescent fibroblasts to iPSCs, karyotyping was done for all three WI-38 derived
101 colonies and six MRC-5 derived colonies. Colony W1 retained diploid karyotype
102 (Figure 1a) while colonies W2 and W3 exhibited heterogeneous karyotypes
103 (Supplementary Figure S1a). All six colonies isolated from MRC-5 (M1 to M6)
104 preserved their diploid phenotype (Figure 1b; Supplementary Figure S1a).

105

106 Colonies W1 and M3, were conveniently selected for further characterisation. We
107 found increased expression of iPSC cell surface marker TRA-1-60 and transcription

108 factor OCT 4 in these colonies (Figure 1c). Reprogramming from fibroblasts to iPSCs
109 was further confirmed at the level of transcription by significantly decreased
110 expression of fibroblast associated genes (*acta2*, *col3a1*, *fsp*, *ltbp2*, *timp1* and *vim*)
111 and increased expression of iPSC gene markers (*dmnt3b*, *htert*, *nanog*, *oct4*, *sox2*
112 and *tdgf1*) relative to the parental fibroblasts (Figure 1d-e).

113

114 A hallmark of cell strains WI-38 and MRC-5 fibroblasts is that they undergo
115 senescence (20) due to lack of expression of human telomerase (hTERT) which
116 prevents telomere shortening. We thus measured hTERT expression in our colonies.
117 Expression of hTERT was upregulated in W1 and M3 iPSCs as compared to their
118 respective parental fibroblasts (Figure 1e).

119

120 Stemness was also validated through measuring alkaline phosphatase (AP) activity,
121 which is present in stem but not differentiated cells. Indeed, parental WI-38
122 fibroblasts stained negative for AP while W1 and M3 iPSCs demonstrated positive
123 pink staining of AP activity (Supplementary Figure S1b).

124

125 We further tested if these iPSCs were indeed pluripotent by showing that these cells
126 were capable of differentiation into the three germ layers. The iPSCs were exposed
127 to differentiation media for either endoderm, ectoderm or mesoderm lineages.
128 Lineage differentiation was confirmed based on increased expression of lineage
129 specific markers (endoderm: *sox17*, *gata6*, *foxa2*; mesoderm: *ncam1*, *hand1*, *msx1*;
130 ectoderm: *otx2*, *pax6*, *lhx2*) (Supplementary figure S1c) matched by decreased
131 expression of iPSC markers (*nanog*, *sox2*, *oct4*) (Supplementary figure S1d). Taken
132 collectively, these multiple lines of evidence suggested that WI-38 and MRC-5 were
133 successfully reprogrammed to W1 and M3 iPSCs.

134

135 **IPSC-derived differentiated cells undergo senescence.** To derive differentiated
136 cells from iPSCs, we added a chemically defined media to the iPSCs and passaged
137 the cells four times (Figure 2a). Stem cell morphology was lost upon differentiation
138 from iPSC to a differentiated cell (Figure 2b). Furthermore, there was a significant
139 decrease in iPSC marker genes upon differentiation in both W1 and M3
140 differentiated cells at every passage post differentiation (Figure 2c-d). However, after
141 four passages, the cells could no longer be maintained in culture and perished.

142 *Figure 2. iPSCs can be differentiated back into cell strains. (A) Schematic depicting*
143 *the protocol for define differentiation of iPSCs. Image made in BioRender. (B-C)*
144 *Quantitative PCR of iPSC marker genes in W1 (B) and M3 (C) iPSCs and the*
145 *differentiated cells derived from these respective iPSCs, at P1-P4. (D) Bright field*
146 *images of W1 cells prior to differentiation, during differentiation and following*
147 *differentiation at passage 1 and 4 at 10X magnification. (E) Hierarchical clustering of*
148 *microarray gene expression from passage 1 to 4 of W1-derived differentiated cells.*
149 ** $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$.*

150

151 To gain insights into the differences between passage 1 (P1) to P4 differentiated
152 cells, we analysed whole genome expression of these cells using microarray.
153 Hierarchical clustering of differentially expressed genes from P1 through P4 of W1
154 differentiated cells revealed distinct patterns at P1 and P4 (Figure 2e). Gene
155 expression patterns at P2 and P3 were intermediate to those of P1 and P4 (Figure
156 2e).

157

158 Pathway analysis of genes differentially expressed at P2, P3 and P4 compared to P1
159 defined the differences between the cells at different passages. Few genes were
160 significantly (adjusted p-value < 0.05) up (n = 14) or down (n=85) regulated from P1
161 to P2. The top hits of upregulated genes were related to cell differentiation processes
162 (Figure 3a), whereas the downregulated genes did not significantly associate with a
163 specific pathway (Supplementary figure 2a). The comparison between P1 against P3
164 and P4 cells yielded interesting findings. Senescence and autophagy in cancer cells
165 emerged as the second top pathway in both analyses (Figure 3a). Other aging-
166 related pathways that were highlighted in our analysis were complement and
167 coagulation cascades, hypothesized pathways in cardiovascular disease and
168 genotoxicity. Interestingly, acute inflammation was also upregulated at P4 (Figure
169 3a), which is supportive of the notion of inflammaging - an increase in basal
170 inflammation in elderly individuals (26). These findings were matched with significant
171 downregulation of pathways associated with DNA replication and the cell cycle
172 (Supplementary figure 2c). Differential expression of genes associated with
173 senescence (*serpine1*) and acute inflammation (*icam1*) were validated by qPCR of
174 W1 and M3 differentiated cells at P1 and P4 (Supplementary figure 2d).

175 *Figure 3. iPSC-derived differentiated cells undergo senescence. (A) Pathway*
176 *analysis of upregulated genes in P1 vs either P2, P3 or P4 of W1 differentiated cells*
177 *using the WikiPathways 2019 Human database. Pathways are shown in order of*
178 *significance, with the most significantly upregulated pathway at the top. (B-C)*
179 *Population doubling time of W1 and M3 differentiated cells at P1 and P4 over 48*
180 *hours of observation.*

181

182 The senescent phenotype was phenotypically validated by measuring population
183 doubling times at passage one and four in differentiated cells. Aging cells have
184 previously been shown to have slower population doubling times. Both W1 and M3-
185 derived differentiated cell demonstrated slower population doubling time at later
186 passages (Figure 3b-c).

187

188 **Differentiated cells but not iPSCs are susceptible to DENV infection.** Stem cells
189 have recently been shown to be less susceptible to viral infection through intrinsic
190 expression of interferon stimulated genes (ISGs) independent of interferon β (IFN β)
191 activity (27). We thus measured a selection of these previously identified ISGs by
192 qPCR in our iPSCs and compared to their parental fibroblasts to ensure that our
193 iPSCs showed the same ISG expression profile as those previously reported (27).
194 We found that the ISGs - *alyfref*, *eif3l*, *pabpc4*, *ptma* and *ybx3* - were intrinsically
195 expressed and were significantly upregulated in the iPSCs compared to their
196 parental fibroblasts (Figure 4a).

197

198 *Figure 4. iPSCs are resistant to flaviviral infection through an IFN β independent*
199 *mechanism. (A) Quantitative PCR of ALYFREF, EIF3L, PABPC4, PTMA and YBX3*
200 *(stem cell interferon independent ISGs) in W1 and M3 iPSCs. Their respective*
201 *parental cell strains were included as controls. (B-C) RT-PCR of genome copies of*
202 *DENV2 16681 and ZIKV HPF/2013 from the supernatant of infected cell strains and*
203 *iPSCs at 72 hours post infection (hpi) in M3 and W1 iPSCs. (D-E) Quantitative PCR*
204 *of interferon and interferon stimulated genes in iPSCs and parental cell strains MRC-*
205 *5 (D) and WI-38(E) infected with ZIKV (HPF/2013) or DENV2 (16681) relative to the*
206 *respective uninfected control cell.*

207

208 Along with the intrinsically expressed ISGs, our iPSCs were less susceptible to
209 DENV and ZIKV infection. Inoculation of wild type DENV2 (16681 strain) and Zika
210 virus (ZIKV) (HPF/2013 strain) onto iPSCs resulted in significantly reduced viral
211 genome copies at 72 hours post infection (hpi) compared to infection in their
212 respective parental fibroblasts (Figure 4b-c). Similar differences were observed when
213 infection was assayed for infectious viral progenies (Supplementary figure 3a).
214 Furthermore, there was a significantly attenuated type I interferon response during
215 infection with both viruses in both iPSCs relative to the original fibroblasts (Figure 4d-
216 e; Supplementary figure 3b-c), consistent with previous observations (27).

217

218 We next asked if cell susceptibility to viral infection could be restored in iPSC-derived
219 differentiated cells. W1 differentiated cells were infected with DENV2 16681, while
220 M3 differentiated cells were infected at passages 1 and 4. We found infectious
221 DENV2 particles in the supernatant of W1 and M3 differentiated cells at 48 hpi
222 (Figure 5a); the plaque titres were, however, not significantly different. DENV2
223 genomic RNA in the supernatant of infected W1 cells showed an increasing trend
224 with increasing number of passages although this difference was also not statistically
225 significant (Figure 5b). No difference was seen in DENV2 16681 RNA levels in P1
226 compared to P4 M3 cells (Figure 5b). These findings thus indicate that susceptibility
227 to DENV infection was restored in iPSC-derived differentiated cells.

228

229 *Figure 5. Susceptibility to DENV infection is restored in iPSC-derived differentiated*
230 *cells. (A) DENV2 16681 progenies produced at 48hpi in P1-P4 W1-derived*
231 *differentiated cells and M3 differentiated cells at P1 and P4. (B) Genomic RNA*
232 *recovered from the supernatant of DENV2 16681 infections at 48hpi in W1- and M3-*
233 *derived differentiated cells. (C) Principal component analysis (PCA) of gene*
234 *expression data from W1 differentiated cells infected with DENV2 or mock infected*
235 *at P1 and P4. P1 cells are shown in smaller dots whereas P4 are larger. (D-E)*
236 *Volcano plot of gene expression changes in DENV2 16681 infected W1-derived*
237 *differentiated cells compared to mock infection at P1 and P4. Values above the*
238 *horizontal line are statistically significant. Vertical lines depict the Log₂ cut off*
239 *assigned to genes that are differentially expressed. (F-G) Quantitative PCR of iPSC*
240 *antiviral genes identified in the microarray analysis (IFIT1, IFI6, IFN β , OAS1,*

241 *CXCL10*) during infection with DENV2 16681 at P1 and P4 in infected and
242 uninfected cells. (H) *IFN β* expression in infected W1 differentiated cells at P1 vs P4.

243

244 **Aging cell related differences in host response to DENV infection.** Given the
245 differences in baseline gene expression upon passage of these iPSC-derived
246 differentiated cells (Figure 3a), we next explored if the host response to DENV2
247 16681 infection was different despite producing similar levels of viral progenies.
248 Gene expression of both infected and mock infected P1 cells clustered together. In
249 contrast, infected P4 cells clustered separately from their mock infected controls
250 (Figure 5c). Only one single gene of unknown function was significantly upregulated
251 in response to DENV2 16681 infection in P1 cells (Figure 5d). This finding is
252 interesting as P1 cells partially resembled CD33+ myeloid cells and would be
253 expected to be more prone to pro-inflammatory response, if the host response to
254 infection was influenced more by cell type rather than age. In contrast, 354 genes
255 were found to be differentially expressed between DENV2 16681 infected and mock
256 infected P4 cells (Figure 5e). Many of these genes showed a large fold change,
257 especially those that belong to the canonical *IFN β* antiviral response pathway
258 (Figure 5e). The differentially expressed *IFN β* and related genes identified in the
259 microarray analysis were validated through qPCR (Figure 5f-g). Indeed, *IFN β*
260 expression was significantly lower in P1 compared to P4 DENV2 infected cells
261 (Figure 5h). The increase in antiviral response at later passages was also observed
262 by qPCR in M3 differentiated cells (Supplementary figure 4).

263

264 To determine if the response of the differentiated cells to infection was generic or
265 specific to DENV2 16681, we examined infection outcome in our iPSC-derived
266 differentiated cells using the attenuated DENV2 PDK53 and YF17D. DENV2 PDK53
267 was derived from its wild-type 16681 parent through *in vitro* serial passaging. Its
268 genome is thus composed of the 16681 genome but with 5 amino acid and 1
269 nucleotide substitutions, the latter in the 5' untranslated region of the genome.
270 Despite these small number of genomic differences, infection with PDK53 produced
271 reduced levels of infectious progenies in higher passaged cells (Figure 6a).
272 Furthermore, unlike 16681 infected P1 cells that showed minimal transcriptional level
273 changes, PDK53 infection induced *IFN β* expression that was greater than 6 Log₂fold

274 change compared to mock infected P1 and P4 cells (Figure 6b). Similar trends were
275 also observed with the expression of ISGs (Figure 6c-d, Supplementary figure 5a-b).

276

277 *Figure 6. Infection outcome in iPSC-derived differentiated cells is virus-specific. (A)*
278 *Infectious DENV2 PDK53 particles 48hpi in W1 differentiated cells at passage 1*
279 *through 4 and M3 differentiated cells at passage 1 and 4. (B) IFN β expression in P1*
280 *and P4 W1- and M3-derived differentiated cells infected with PDK53. (C-D) IFIT1,*
281 *IFI6, IFN β , OAS1, CXCL10 gene expression upon DENV2 PDK53 compared to*
282 *mock infection in P1 (C) and P4 (D) M3-derived differentiated cells. (E) YF17D*
283 *infectious viral progeny recovered at 48 hpi in P1-P4 W1-derived differentiated cells.*
284 *(F-G) W1-derived differentiated cells IFIT1, IFI6, IFN β , OAS1, CXCL10 gene*
285 *expression at 48 hours post YF17D infection. (H) YF17D infected W1-differentiated*
286 *cell's IFN β expression at P1 vs P4.*

287

288 Infection with the YF17D produced the opposite trend compared to PDK53. YF17D
289 infection showed increased virus replication with increasing passage number of
290 differentiated cells (Figure 6e; Supplementary figure 5c) despite increased
291 expression of IFN β and ISGs (Figure 5f-h; Supplementary figure 5d-f). This
292 observation is particularly interesting as YF17D vaccination is known to be
293 associated with increased risk of viscerotropic infection and disease in older adults
294 (28). Collectively, our findings suggest that the host response to infection is not
295 generic in our iPSC-derived differentiated cells but are rather age-dependent and
296 could potentially inform on age-related host response to flaviviral infection.

297

298

299 DISCUSSION

300

301 Dengue in older adults have shown worse clinical outcome compared to their
302 younger counterparts (11). DENV infection in elderly patients often presents
303 atypically and complicates clinical diagnosis (8, 15, 29). They are also more likely to
304 have had prior exposure to DENV and are thus at greater risk of antibody-dependent
305 enhancement upon secondary infection with a heterologous DENV (30) (31). The
306 prevalence of co-morbidities, such as diabetes and hypertension, increase with age
307 and several of these have been linked with increased risk of severe dengue (16, 17,
308 32). However, there could also exist age-related host factors, including
309 immunosenescence, the decline of the immune system with age, or inflammaging,
310 an increase in basal inflammation with age, that may elevate the risk of older
311 individuals to severe dengue (33). Thus, despite the known poorer clinical outcome
312 of dengue in older adults, the pathogenic underpinnings of DENV infection in aged
313 cells have remained undefined.

314

315 A major limiting step to understanding age-related differences in host-virus interactions
316 is the lack of suitable *in vitro* tools to simulate senescence. Commonly used cell lines
317 are immortal and thus poorly reflect the processes of aging. Cell strains, such as WI-
318 38 and MRC-5 undergo senescence (20, 24). Age associated changes in gene
319 expression may influence outcome of DENV infection. Indeed senescent monocytes
320 have been shown to have increased DENV susceptibility via increased expression of
321 receptor DC-SIGN (34). Moreover, cell strains also have the advantage of having
322 diploid genomes that could be more accurate than cell lines in reflecting the
323 transcriptional responses that happens in dengue patients. Unfortunately, due to their
324 limited lifespan, global stocks of these diploid cell strains are limited. WI-38 diploid
325 fibroblasts have been used to near exhaustion since their isolation. Thus, remaining
326 supplies are constrained to high passaged senescent cells (21, 24). Without ready
327 access to paired low and high passaged cells, WI-38 and MRC-5 have limited potential
328 as tools to dissect age-related host-virus interactions that underpin pathogenesis. Our
329 work thus overcomes this limitation through the derivation of iPSCs from WI-38 and
330 MRC-5. The reprogrammed iPSCs could be differentiated and passaged for infection
331 experiments.

332

333 We have used a chemically defined media to differentiate the iPSCs into an adherent
334 cell monolayer, that was followed through serial passaging. We have used this
335 relatively straightforward approach as a proof-of-concept demonstration of W1-38 and
336 MRC-5 derived iPSCs and iPSC-derived differentiated cells as *in vitro* models to study
337 age-related effects on viral infection. Indeed, our transcriptional analysis showed that
338 the baseline expression of aging-related genes were increased upon passaging of W1
339 and M3 cells. To our knowledge, such an approach to derive isogenic cells of different
340 replicative ages for infection studies has not been previously attempted. Future studies
341 could make use of better defined differentiation protocols using well established kits.
342 Alternatively, iPSCs could also be differentiated through the use of transcriptions
343 factors computationally predicted by mognify (35) or epimognify (36). Furthermore, as
344 the process of differentiation does not occur uniformly throughout a culture, single-cell
345 sequencing would enable us to compare homogenous cell types within a
346 heterogeneous population at various replicative ages.

347

348 We found interesting differences in the virologic outcome and host response to
349 infection in both W1- and M3-derived cells. DENV2 16681 infection produced no
350 difference in the amount of progeny virus across the different passages iPSC-
351 derived differentiated cells. Conversely, infection with its attenuated derivative,
352 DENV2 PDK53, produced significantly reduced viral progenies with increasing
353 number of passages. This finding is interesting as we have previously found DENV2
354 PDK53 infection to be restricted by the innate immune response, which may also
355 explain its attenuated phenotype (37, 38). Despite the production of comparable
356 levels of DENV2 16681, infection with this virus in P1 to P4 iPSC-derived
357 differentiated cells produced vastly different responses in gene expression. P4 cells
358 produced more genes with greater fold change in infected compared to uninfected
359 cells than P1 cells. Many of these genes, such as *il1a* or *serpine1*, are in the innate
360 immune and pro-inflammatory pathways. These findings suggest that for any given
361 viral load, older adults may respond differently compared to the younger dengue
362 patients with a more pronounced inflammatory response and hence explain their
363 increased risk in severe dengue.

364

365 The possibility that this *in vitro* approach could reflect, at least partially, age-related
366 clinical outcome of infection is further supported by our observations on YF17D

367 infection. Vaccination of individuals over 60 years of age with YF17D has been
368 linked with severe adverse events (18) and viscerotropic disease (28), the latter
369 possibly explained by increased burden of live attenuated YF17D infection. YF17D
370 infection in our passaged cells produced higher levels of infectious particles with
371 increasing number of passages. The increase in YF17D progenies occurred despite
372 increased IFN β expression at later passages. This observation suggests that other
373 YF17D-host interactions may underpin infection outcome in aged cells and hence
374 alter their risk of severe adverse events following YF17D vaccination.

375

376 In conclusion, our findings suggest the feasibility of using iPSC-derivatives of WI-38
377 and MRC-5 cell strains as a resource to elucidate how aging impact host-virus
378 interactions that underpin dengue and other flaviviral pathogenesis.

379

380

381 **MATERIALS AND METHODS**

382 **Cells and culture conditions.** Human diploid fibroblast WI-38 (female) and MRC-5
383 (male) cell strains were maintained in fibroblasts growth media (Minimum Essential
384 Media, 10% FCS, 1% GlutaMAX, 1% penicillin/streptomycin) at 37°C, 20% O₂, 5%
385 CO₂. Cell strains were passaged with TrypLE™ Expression Enzyme. BHK21 cells used
386 for plaque assay were grown in RMPI Medium 1640 (Gibco), 2% FCS and 1%
387 penicillin/streptomycin at 37°C, 20% O₂, 5% CO₂.

388
389 All stem cells were cultivated on 1% Geltrex™ coated cell culture ware in mTeSR™1
390 or TeSR™-E8™ media for maintenance. Stem cells were passaged according to
391 manufacturers' recommendations with ACCUTASE™ or ReLeSR™ where appropriate.
392 Briefly, spent media was removed from the stem cells and ReLeSR™ was added and
393 incubated at room temperature for one minute. ReLeSR™ was then removed, cells
394 were incubated at 37°C, 20% O₂, 5% CO₂ for 6:30min, fresh media was added gently,
395 and cells were re-suspended by tapping the plate for 1min. ACCUTASE™ was added
396 to cells and incubated for 7min at 37°C, 20% O₂, 5% CO₂. Cells were resuspended,
397 transferred to a conical tube and spun at 250 x g for 5min at room temperature. The
398 ACCUTASE™ was then removed and cells were re-suspended in desired media with
399 10µM ROCK inhibitor Y-27632.

400
401 **Virus stocks.** Dengue strains (DENV2 16681 and DENV2 PDK53) were gifted by Dr
402 Claire Huang (Centre for disease control and prevention, USA). Clinical isolate Zika
403 virus HPF13/2013 (KJ776791) was acquired by the European Virus Archive. Yellow
404 fever YF17D was isolated from a vial of Stamaril® live attenuated vaccine. All flavivirus
405 stocks were maintained in insect C6/36 cells at 30°C.

406
407 **Reprogramming diploid fibroblasts to iPSCs.** Human diploid fibroblast cell strains
408 WI-38 and MRC-5 were reprogrammed to iPSCs using the StemRNA™-NM
409 reprogramming kit according to manufacturers' instructions for adult and neonatal
410 human fibroblasts. Briefly, cell strains were seeded on 6 well plates coated with 1%
411 Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane Matrix at a
412 density of 2 x 10⁵ cells per well in fibroblast expansion media (Advanced DMEM, 10%

413 FCS, 1% Glutamax) and incubated at 20% O₂, 37°C overnight. Subsequently, spent
414 media was replaced with NutriStem Media and incubated in at 37°C for 6 hours prior
415 to introduction of the NM-RNA reprogramming cocktail with Lipofectamine[®]RNAiMAX[™]
416 Transfection Reagent in Opti-MEM[®] Reduced Serum Medium. Fresh Nutristem Media
417 and NM-RNA reprogramming cocktail was refreshed daily for the course of four days.
418 Cells were subsequently maintained in Nurtistem media until iPSC colonies could be
419 identified (~14 days). Contrary to manufacturer's instructions, reprogramming was
420 carried out at 20% O₂ rather than ≤5% O₂.

421
422 Potential colonies of iPSCs were manually isolated using a micropipette with a 20μl
423 tip and transferred to a fresh 1% Geltrex[™] coated 6 well plate containing mTeSR[™]1
424 maintenance media for propagation according to manufacturers' instructions.

425
426 **Gene expression quantification.** Relative changes in gene expression of lineage
427 specific markers were measured by qPCR. Briefly, cellular RNA was isolated following
428 the RNeasy Mini Kit, and converted to cDNA via qScript standard protocol. QPCR
429 were performed using LightCycler[®] 480 SYBR Green I Master under the conditions on
430 LightCycler[®] 480 II using LightCycler[®] 480 software (v.1.5). Gene expression primers
431 can be found in supplementary table 1.

432
433 **Immunofluorescent assay.** Primary antibodies against iPSC markers TRA-1-60
434 (ab16288, Abcam[®], 1/500) and OCT4 (ab181557, Abcam[®], 1/250) were used for
435 immunofluorescence assays to determine the expression of stem cell proteins in
436 iPSCs or fibroblasts. Spent media was removed, cells were washed once with PBS
437 and subsequently dislodged using ACCUTASE[™] according to manufacturers'
438 instructions. The cells were spun down at 250 x g for 5min at room temperature and
439 the supernatant was decanted. Pelleted cells were re-suspended in 250μL PBS. Two
440 microliters of re-suspended cells were aliquoted on to 30 well microscope slides
441 (TEKDON incorporated, Slide ID:30-30), allowed to air dry and fixed in acetone for
442 10min at room temperature. Slides were washed in a 50mL conical tube containing
443 PBS for 5min at room temperature three times before primary antibody was applied
444 and incubated for 1-2 hours at 37°C. The slides were washed three times with PBS at
445 room temperature for 5 minutes. Anti-mouse or anti-rabbit secondary antibody was

446 applied where appropriate and incubated for 30 minutes at 37°C. Slides were rinsed
447 with PBS at room temperature for 5 minutes three times. The SlowFade™ Antifade Kit
448 was used as a mounting medium as well as to stain the cellular DNA with DAPI. Slides
449 were visualised on a Nikon Eclipse 80i microscope with Nikon Intensilight C-HGFI at
450 10X magnification and imaged with Nikon Digital Sight camera using NIS Elements
451 Imaging Software (v.3.22.15).

452

453 **Trilineage differentiation of iPSCs.** Pluripotency was confirmed using STEMdiff™
454 Trilineage Differentiation Kit according to manufacturers' instructions. Stem cells were
455 harvested using ACCUTASE™ and seeded on 24 well plates coated with 1% Geltrex
456 at 1×10^5 cells per well for mesoderm differentiation and 1×10^5 cells per well for
457 ectoderm and endoderm differentiation in their respective differentiation medium.
458 Differentiation to endoderm, ectoderm and mesoderm was assessed by qPCR as
459 described earlier using lineage specific primers (Supplementary table 1).
460 Differentiated cells gene expression was assessed against undifferentiated iPSC
461 control.

462

463 **Stem cell differentiation.** The spent medium of W1 iPSCs was removed and the cells
464 were treated with ACCUTASE™ and incubated for 7min at 37°C, 20% O₂, 5% CO₂.
465 Cells were dislodged, transferred to a 15mL conical tube, spun at 250 x g for 5 min at
466 room temperature, the supernatant was decanted and pelleted cells were re-
467 suspended in 3mL TeSR™-E8™ in the presence of 10µM Y-27632. Cells were later
468 seeded on 6 wells plates coated with 1% Geltrex™ at a density of 2×10^5 cells/well in
469 TeSR™-E8™ supplemented with Y-27632 and kept at 37°C, 5% CO₂. Two days later,
470 spent medium was removed and replaced with differentiation medium (DMEM/F12,
471 1% ITS, 0.001nM isoprenaline, 100ng/mL BMP-4, 20ng/mL bFGF and 0.1µM Retinoic
472 acid) and incubated at 37°C, 20% O₂, 5% CO₂ for four days. Cells were then imaged
473 and maintained in culture or the RNA was extracted for qPCR to assess iPSC markers
474 as previously described. Differentiated cells were maintained in DMEM supplemented
475 with 1% Penicillin/streptomycin, 10% Foetal calf serum, 1mM L-glutamine at 37°C, 5%
476 CO₂ thereafter.

477

478 **Alkaline Phosphatase Activity.** Undifferentiated cells were characterized by
479 upregulated alkaline phosphatase activity compared to terminally differentiated cells.
480 Human diploid fibroblasts and iPSCs were seeded in triplicates at 1×10^5 cells/well of
481 fibroblasts or 200 clumps/well for the iPSCs. Alkaline phosphatase activity was
482 measured using the StemAb Alkaline Phosphatase Staining Kit II in accordance with
483 manufactures' guidelines. Cells were imaged on an Olympus DP71 with Olympus
484 TH4-200 camera and recorded with CellSens imaging software.

485

486 **Viral infections.** Infections were performed on senescent cells strains, iPSCs and
487 differentiated with dengue 2 wild type strain 16681, dengue 2 vaccine strain PDK53,
488 Zika wild type stain HPF/2013 or yellow fever vaccine strain 17D. Fibroblasts were
489 seeded in a 24 well plate and kept at 37°C, 20% O₂, 5% CO₂ overnight. Spent medium
490 was removed, cells were counted and infected at an MOI of 1 for 1hour at 37°C, 5%
491 CO₂ in MRC-5 and WI-38 fibroblasts as well as their respective iPSCs. Differentiated
492 cells were infected with virus at an MOI of 0.1 for 1 hour in 37°C, 5% CO₂. Virus
493 inoculum was removed and replaced with fresh media. Fibroblasts and differentiated
494 cells were incubated at 37°C, 5% CO₂ for 48 hours while iPSCs were incubated for 72
495 hours. The supernatant was harvested for plaque assay and qRT-PCR of the viral
496 genome. Cells were collected for RNA extraction followed by qRT-PCR.

497

498 **Infection quantification.** Infectious particle quantification was determined via plaque
499 assay. Briefly, BHK21 cells were seeded at 2×10^5 cells/well in a 24 well plate in RPMI
500 medium supplemented with 2% FCS and 1% penicillin/streptomycin. Once confluency
501 was reached, the BHK21 cells were infected with a 10-fold serial dilution of 100 μ L of
502 virus and incubated at 37°C, 20% O₂, 5% CO₂ for 1 hour, with plate agitation at 15
503 minute intervals. Subsequently, viral inoculum was removed, 0.8% carboxymethyl
504 cellulose (CMC) in RPMI medium supplemented with 3% FCS and
505 penicillin/streptomycin was added and plates were incubated at 37°C, 20% O₂, 5%
506 CO₂ for six days. Cells were then fixed in 20% formalin for at least 30 minutes before
507 rinsing with water. Plates treated with 1% crystal violet (Sigma-Aldrich), washed and
508 air-dried to count plaques.

509

510 Viral genome copy number was quantified by qRT-PCR using CDC primers and
511 probes as previously described for dengue virus (39) and zika virus (40). Briefly,
512 virus genomic RNA was extracted from the supernatant using QIAamp Viral RNA
513 Mini Kit according to manufacturer's instructions. Purified RNA was then quantified
514 by qPCR following the qScript One-Step RT-PCR Kit protocol using the CDC
515 specified primers and probes on the LightCycler® 480 II.

516

517 **Microarray analysis.** RNA was extracted from infected and uninfected differentiated
518 cells at 48 hours post infection using the RNeasy Micro Kit. Microarray analysis was
519 done using the GeneChip™ Human Gene 2.0 ST array. Analysis was carried out using
520 the Partek® gene expression suit. A list of differentially expressed genes were
521 selected based on a FDR adjusted p-value of <0.05 and a gene expression difference
522 of at least Log₂fold-change of 2. Hierarchical clustering was carried out on the genes
523 lists generated. Pathway analysis was done on Enrichr using WikiPathways.

524

525 **Population doubling of differentiated cells.** Cells were seeded at 5×10^4 cells/well
526 in a 24 well plate. At 24 hours and 48 hours, cells were washed with PBS and treated
527 with trypsin. The dislodged cells were counted in triplicate. Population doubling time
528 was calculated from the number of cells at 0, 24 and 48 hours post seeding.

529

530 **Quantification and statistical analysis** – All statistical analyses were performed
531 using GraphPad Prism (v.8.2.1). Student t-test was used and p-value of ≤ 0.05 was
532 considered significant (ns > 0.05, * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$).
533 Statistics depicted on graphs show the mean and standard deviation about the mean
534 unless stated otherwise. All data points shown are biological replicates, unless
535 otherwise stated in the figure legend.

536

537 **ACKNOWLEDGEMENTS**

538 The authors would like to thank Claire Huang from the Centers for Diseases Control
539 and Prevention gifting the DENV strains used in this paper. AMB is supported by a
540 graduate studentship from Duke-NUS Medical School. EEO receives salary support
541 from the National Medical Research Council of Singapore, through the Clinician-
542 Scientist (Senior Investigator) Award.

543

544 REFERENCES

- 545 1. Kroeger A, Nathan M, Hombach J, World Health Organization TDRRGoD. Dengue.
546 *Nat Rev Microbiol.* 2004;2(5):360-1.
- 547 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The
548 global distribution and burden of dengue. *Nature.* 2013;496(7446):504-7.
- 549 3. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The
550 current and future global distribution and population at risk of dengue. *Nat Microbiol.*
551 2019;4(9):1508-15.
- 552 4. Verhagen LM, de Groot R. Dengue in children. *J Infect.* 2014;69 Suppl 1:S77-86.
- 553 5. Huy R, Buchy P, Conan A, Ngan C, Ong S, Ali R, et al. National dengue surveillance
554 in Cambodia 1980-2008: epidemiological and virological trends and the impact of vector
555 control. *Bull World Health Organ.* 2010;88(9):650-7.
- 556 6. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in
557 Singapore. *Emerg Infect Dis.* 2006;12(6):887-93.
- 558 7. Egger JR, Ooi EE, Kelly DW, Woolhouse ME, Davies CR, Coleman PG.
559 Reconstructing historical changes in the force of infection of dengue fever in Singapore:
560 implications for surveillance and control. *Bull World Health Organ.* 2008;86(3):187-96.
- 561 8. Low JG, Ong A, Tan LK, Chatterji S, Chow A, Lim WY, et al. The early clinical
562 features of dengue in adults: challenges for early clinical diagnosis. *PLoS Negl Trop Dis.*
563 2011;5(5):e1191.
- 564 9. Huy BV, Hoa LNM, Thuy DT, Van Kinh N, Ngan TTD, Duyet LV, et al.
565 Epidemiological and Clinical Features of Dengue Infection in Adults in the 2017 Outbreak in
566 Vietnam. *Biomed Res Int.* 2019;2019:3085827.
- 567 10. Hsu JC, Hsieh CL, Lu CY. Trend and geographic analysis of the prevalence of
568 dengue in Taiwan, 2010-2015. *Int J Infect Dis.* 2017;54:43-9.
- 569 11. Ang LW, Thein TL, Ng Y, Boudville IC, Chia PY, Lee VJM, et al. A 15-year review
570 of dengue hospitalizations in Singapore: Reducing admissions without adverse consequences,
571 2003 to 2017. *PLoS Negl Trop Dis.* 2019;13(5):e0007389.
- 572 12. Rowe EK, Leo YS, Wong JG, Thein TL, Gan VC, Lee LK, et al. Challenges in
573 dengue fever in the elderly: atypical presentation and risk of severe dengue and hospital-
574 acquired infection [corrected]. *PLoS Negl Trop Dis.* 2014;8(4):e2777.
- 575 13. Garcia-Rivera EJ, Rigau-Perez JG. Dengue severity in the elderly in Puerto Rico. *Rev*
576 *Panam Salud Publica.* 2003;13(6):362-8.
- 577 14. Leo YS, Thein TL, Fisher DA, Low JG, Oh HM, Narayanan RL, et al. Confirmed
578 adult dengue deaths in Singapore: 5-year multi-center retrospective study. *BMC Infect Dis.*
579 2011;11:123.
- 580 15. Vicente CR, Cerutti Junior C, Froschl G, Romano CM, Cabidelle AS, Herberinger KH.
581 Influence of demographics on clinical outcome of dengue: a cross-sectional study of 6703
582 confirmed cases in Vitoria, Espirito Santo State, Brazil. *Epidemiol Infect.* 2017;145(1):46-53.
- 583 16. Figueiredo MA, Rodrigues LC, Barreto ML, Lima JW, Costa MC, Morato V, et al.
584 Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control
585 study. *PLoS Negl Trop Dis.* 2010;4(6):e699.
- 586 17. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, et al. Diabetes with
587 hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue
588 serotype 2 epidemic: a case control study. *PLoS Negl Trop Dis.* 2012;6(5):e1641.
- 589 18. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow
590 fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse
591 events. *Vaccine.* 2005;23(25):3256-63.

- 592 19. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, et al. Advanced age a
593 risk factor for illness temporally associated with yellow fever vaccination. *Emerg Infect Dis.*
594 2001;7(6):945-51.
- 595 20. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains.
596 *Experimental cell research.* 1961;25:585-621.
- 597 21. Nicholas W. Hayflick's Tragedy: The Rise and Fall of a Human Cell Line. *Science.*
598 1976;192:125-7.
- 599 22. Jacobs JP, Jones CM, Baille JP. Characteristics of a Human Diploid Cell Designated
600 MRC-5
601 . *Nature.* 1970;227:3.
- 602 23. Olshansky SJ, Hayflick L. The Role of the WI-38 Cell Strain in Saving Lives and
603 Reducing Morbidity. *AIMS Public Health.* 2017;4(2):127-38.
- 604 24. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. *Nature.* 2000;1:72-6.
- 605 25. Poleganov AM, Eminli S, Beissert T, Herz S, Moon JI, Goldman J, et al. Efficient
606 Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells
607 Using Nonmodified RNA for Reprogramming and Immune Evasion. *Human Gene Therapy.*
608 2015;26(11):751-66.
- 609 26. Ferrucci L, Fabbri E. Inflammaging: chronic inflammation in ageing, cardiovascular
610 disease, and frailty. *Nat Rev Cardiol.* 2018;15(9):505-22.
- 611 27. Wu X, Dao Thi VL, Huang Y, Billerbeck E, Saha D, Hoffmann HH, et al. Intrinsic
612 Immunity Shapes Viral Resistance of Stem Cells. *Cell.* 2018;172(3):423-38 e25.
- 613 28. Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated
614 viscerotropic disease among the elderly: a systematic review. *Vaccine.* 2013;31(49):5798-
615 805.
- 616 29. Lee CC, Hsu HC, Chang CM, Hong MY, Ko WC. Atypical presentations of dengue
617 disease in the elderly visiting the ED. *Am J Emerg Med.* 2013;31(5):783-7.
- 618 30. Ang LW, Cutter J, James L, Goh KT. Seroepidemiology of dengue virus infection in
619 the adult population in tropical Singapore. *Epidemiol Infect.* 2015;143(8):1585-93.
- 620 31. Chan KR, Wang X, Saron WA, Gan ES, Tan HC, Mok DZ, et al. Cross-reactive
621 antibodies enhance live attenuated virus infection for increased immunogenicity. *Nat*
622 *Microbiol.* 2016:16164.
- 623 32. Thein TL, Leo YS, Fisher DA, Low JG, Oh HM, Gan VC, et al. Risk factors for
624 fatality among confirmed adult dengue inpatients in Singapore: a matched case-control study.
625 *PLoS One.* 2013;8(11):e81060.
- 626 33. Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, et al. Immune
627 system, cell senescence, aging and longevity--inflamm-aging reappraised. *Curr Pharm Des.*
628 2013;19(9):1675-9.
- 629 34. Hsieh TH, Tsai TT, Chen CL, Shen TJ, Jhan MK, Tseng PC, et al. Senescence in
630 Monocytes Facilitates Dengue Virus Infection by Increasing Infectivity. *Front Cell Infect*
631 *Microbiol.* 2020;10:375.
- 632 35. Rackham OJ, Firas J, Fang H, Oates ME, Holmes ML, Knaupp AS, et al. A predictive
633 computational framework for direct reprogramming between human cell types. *Nat Genet.*
634 2016;48(3):331-5.
- 635 36. Kamaraj US, Chen J, Katwadi K, Ouyang JF, Yang Sun YB, Lim YM, et al.
636 EpiMogrify Models H3K4me3 Data to Identify Signaling Molecules that Improve Cell Fate
637 Control and Maintenance. *Cell Syst.* 2020;11(5):509-22 e10.
- 638 37. Choy MM, Ng DHL, Siriphanitchakorn T, Ng WC, Sundstrom KB, Tan HC, et al. A
639 Non-structural 1 Protein G53D Substitution Attenuates a Clinically Tested Live Dengue
640 Vaccine. *Cell Rep.* 2020;31(6):107617.

- 641 38. Goh KC, Tang CK, Norton DC, Gan ES, Tan HC, Sun B, et al. Molecular
642 determinants of plaque size as an indicator of dengue virus attenuation. *Sci Rep*.
643 2016;6:26100.
- 644 39. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses
645 in a fourplex real-time reverse transcriptase PCR assay. *J Clin Microbiol*. 2005;43(10):4977-
646 83.
- 647 40. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic
648 and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia,
649 2007. *Emerg Infect Dis*. 2008;14(8):1232-9.
650




Figure 1




Figure 2

A Up regulated pathways at passage 1 vs 2 (14)

Corticotropin-releasing hormone signaling pathway WP2355
 Hematopoietic Stem Cell Differentiation WP2849
 Hair Follicle Development: Cytodifferentiation (Part 3 of 3) WP2840
 TGF-beta Signaling Pathway WP366
 EGF/EGFR Signaling Pathway WP437
 Serotonin and anxiety-related events WP3944
 Serotonin and anxiety WP3947
 TGF-beta Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition WP3859
 Estrogen signaling pathway WP712
 Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612


Up regulated pathways at passage 1 vs 3 (133)

Complement and Coagulation Cascades WP558
 Senescence and Autophagy in Cancer WP615
 Primary Focal Segmental Glomerulosclerosis FSGS WP2572
 Hair Follicle Development: Cytodifferentiation (Part 3 of 3) WP2840
 Blood Clotting Cascade WP272
 Hematopoietic Stem Cell Differentiation WP2849
 miRNA regulation of p53 pathway in prostate cancer WP3982
 Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668
 DNA Damage Response (only ATM dependent) WP710
 Vitamin D Receptor Pathway WP2877


Up regulated pathways at passage 1 vs 4 (444)

Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668
 Senescence and Autophagy in Cancer WP615
 Genotoxicity pathway WP4286
 Cells and Molecules involved in local acute inflammatory response WP4493
 Platelet-mediated interactions with vascular and circulating cells WP4462
 Differentiation Pathway WP2848
 Nuclear Receptors Meta-Pathway WP2882
 Primary Focal Segmental Glomerulosclerosis FSGS WP2572
 Hippo-Merlin Signaling Dysregulation WP4541
 PI3K-Akt Signaling Pathway WP4172

B



C






Figure 4




Figure 5




Figure 6

651 **Supplementary Figures Legends**

652 **Supplementary figure 1. Senescent fibroblast reprogrammed into iPSCs. (A)**
653 MRC-5 derived iPSC colonies M1, M2, M4, M5 and M6 karyograms depicting normal
654 male karyotype. Aberrant karyotype of WI-38 derived iPSC colony W2 and W3 with
655 anomalies in translocation or chromosome copy number indicated on the karyogram.
656 (GTG-banded cells analyzed, n=20. Karyograms made, n=5). **(B)** Alkaline
657 phosphatase staining in WI-38 and W1 iPSC as well as MRC-5 and M3 iPSC. Cells
658 with elevated phosphatase activity stained red/pink. **(C-D)** Quantitative PCR analysis
659 of tri-lineage differentiation of W1 and M3 iPSCs into mesoderm, endoderm and
660 ectoderm using appropriate lineage specific markers (C) and iPSC markers (D).
661 Student t-test (n = 3) was used for statistical analysis * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq$
662 0.001, **** $p \leq 0.0001$.

663
664 **Supplementary figure 2. Differentiated cells exhibit hallmarks of aging. (A)**
665 Quantitative PCR of senescence associated genes in W1- and M3-derived
666 differentiated cells at P1 and P4 (each dot represents 1 replicate). **(B-D)** Pathway
667 analysis of downregulated genes in P2 (B), P3 (C) and P4(D) of W1 differentiated
668 cells compared to P1 using the WikiPathways 2019 Human database. Significantly
669 enriched downregulated pathways are coloured blue with the most significant ones
670 shown at the top. Pathways that did not meet statistical significance of $p < 0.05$ are
671 shown in gray.




672
673 **Supplementary figure 3. Flaviviral infection and IFN β response in cells strains**
674 **and cell strain derived iPSCs at 72 hpi.** Cell strains produce more infectious
675 particles and a larger type I IFN response than their iPSC derivatives. **(A)** Zika
676 HPF/2013 and DENV2 16681 infectious particles produced in WI-38 and W1 iPSCs
677 at 72 hpi. **(B-C)** Quantitative PCR of IFN and ISGs in W1 (B) and M3 (C) iPSCs as
678 well as their respective parental cell strains with or without ZIKV and DENV infection.
679 Student t-test (n = 3) was used for statistical analysis * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq$
680 0.001, **** $p \leq 0.0001$

681
682 **Supplementary figure 4. The immune response to DENV2 16681 infection**
683 **differs with in vitro passage of M3-derived differentiated cells. (A-B)** Gene
684 expression of IFIT1, IFI6, IFN β , OAS1, CXCL10, determined by qPCR, during
685 DENV2 16681 infection in P1 (A) and P4 (B) M3-derived differentiated cells with or
686 without DENV2 16681 infection. **(C)** IFN β expression in infected M3-derived
687 differentiated cells at P1 and P4.


688
689 **Supplementary figure 5. The immune response to DENV2 PDK53 is consistent**
690 **across passage number while YF17D generates a greater IFN β at passage 4.**
691 **(A-B)** Gene expression of IFIT1, IFI6, IFN β , OAS1, CXCL10, determined by qPCR
692 following DENV2 PDK53 or mock infection in P1 (A) and P4 (B) M3-derived
693 differentiated cells. **(C)** Plaque titres of YF17D at 48hpi in M3 differentiated cells at
694 passage 1 and 4. **(D-E)** Expression of genes in the canonical IFN β response
695 pathway (IFIT1, IFI6, IFN β , OAS1, CXCL10) presented as Log₂fold change in YF17D
696 infected compared to uninfected cells, at P1 (D) and P4 (D) in M3- and W1-derived
697 differentiated cells. **(F)** IFN β gene expression at P1 and P4 M3- and W1-derived
698 differentiated cells infected with YF17D and normalized to their respective uninfected
699 controls.

A MRC-5 derived iPSCs


WI-38 derived iPSCs



C




D




Supplementary figure 1. Senescent fibroblast reprogrammed into iPSCs


A




B Down regulated pathways at passage 1 vs 2 (85)



C Down regulated pathways at passage 1 vs 3 (332)




D Down regulated pathways at passage 1 vs 4 (821)




Supplementary figure 2. Differentiated cells exhibit hallmarks of aging

A

ZIKV HPF/2013 infectious particles




DENV2 16681 infectious particles




B

ZIKV HPF/2013




DENV2 16681




C

ZIKV HPF/2013




DENV2 16681




Supplementary figure 3. Flaviviral infection and IFN β response in cells strains and cell strain derived iPSCs at 72 hpi


A




B



C



Supplementary figure 4. The immune response to DENV2 16681 infection differs with in vitro passage of M3-derived differentiated cells.



Supplementary figure 5. The immune response to DENV2 PDK53 is consistent across passage number while YF17D generates a greater IFN β at passage 4

#	Name	Direction	Sequence	Source	#	Name	Direction	Sequence	Source
1	dmnt3b	F	CCCAGCTCTACCTTACCATCG	PrimerBank	41	ncam1	F	AGGAGACAGAAACGAAGCCA	PrimerBank
2		R	GGTCCCTATTCCAAACTCCT		42		R	GGTGTGGAAATGCTCTGGT	
3	htert	F	CCGATTGTGAACATGGACTACG	J. Liu et al., (2015)	43	ifn	F	GCTTGGATTCTACAAAGAAGCA	PrimerBank
4		R	CACGCTGAACAGTGCCTTC		44		R	ATAGATGGTCAATGCGGCGTC	
5	oct4	F	CACTAAGGAAGGAATTGGGAACA	PrimerBank	45	mx1	F	GTTTCCGAAGTGAGCATCGCA	PrimerBank
6		R	GGGATTAATAACAAGGACATATTG		46		R	CTGCACAGGTGTCTCAGC	
7	nanog	F	TTTGTGGCCCTGAAGAAAAC	PrimerBank	47	cxcl10	F	GTGGCATTCAAGGAGTACCTC	PrimerBank
8		R	AGGGCTGTCTCGAATAAGCAG		48		R	TGATGGCCTCGATTCTGGATT	
9	sox2	F	TACAGCATGTCTACTCGCAG	PrimerBank	49	alyref	F	TATGATCGCTCTGGTCGAG	PrimerBank
10		R	GAGGAAGAGGTAAACCACAGGG		50		R	AGAGGGACGCCGTTGTACT	
11	tdgf	F	CCCTCTTCTACGGACGGAA	PrimerBank	51	eif3l	F	GGAGGAGATTGACTTTCTTCGTT	PrimerBank
12		R	CAGGGAACACTCTTGGCAG		52		R	TTGATTTGTCTACCAGGGAATG	
13	acta2	F	AAAAGACAGCTACGTGGGTGA	PrimerBank	53	pabpc4	F	AAGCCAATCCGCATCATGTG	PrimerBank
14		R	GCCATGTTCTATCGGGTACTTC		54		R	CTCTTGGGTCTCGAAGTGGAC	
15	Col3a1	F	TTGAAGGAGGATGTTCCCATCT	PrimerBank	55	ptma	F	GGAGGCTGACAATGAGGTAGA	PrimerBank
16		R	ACAGACACATATTTGGCATGGTT		56		R	TGGTATCGACATCGTCATCCT	
17	fsp	F	GATGAGCAACTGGACAGCAA	PrimerBank	57	ybx3	F	ACCGGCGTCCCTACAATTAC	PrimerBank
18		R	CTGGGTGCTTATCTGGGAG		58		R	GGTTCAGTTGGTCTTCAC	
19	Itbp2	F	AGCACCAACCCTGATCAAAC	PrimerBank	59	if16	F	GGTCTGCGATCCTGAATGGG	PrimerBank
20		R	CTCATCGGGAATGACCTCCTC		60		R	TCACTATCGAGATACTTGTGGGT	
21	timp1	F	AGAGTGCTGCGGATACTTCC	PrimerBank	61	ifit1	F	TTGATGACGATGAAATGCCTGA	PrimerBank
22		R	CCAACAGTGTAGTCTTGGTG		62		R	CAGGTCACCAGACTCCTCAC	
23	vim	F	TGCCGTTGAAGCTGCTAACTA	PrimerBank	63	oas1	F	TGCCAAGGTGGTAAAGGGTG	PrimerBank
24		R	CCAGAGGGAGTGAATCCAGATTA		64		R	CCGGCGATTTAACTGATCCTG	
25	otx2	F	CAAAGTGAGACTGCCAAAAGA	PrimerBank	65	serpine1	F	CCTGGGCCTTACAGGAAGG	PrimerBank
26		R	TGGACAAGGGATCTGACAGTG		66		R	GGTCCGATTCTCGTCAATAAAC	
27	lhx2	F	ATGCTGTTCCACAGTCTGTCG	PrimerBank	67	cdkn1a	F	GATCCAGCACATGAGCCAAG	PrimerBank
28		R	GCATGGTCTCTCGGTGTC		68		R	AAGGTCGCAAGGATTGTTTG	
29	pax6	F	TGGGCAGGTATTACGAGACTG	PrimerBank	69	gabarapl1	F	ATGAAGTTCAGTACAAGGAGGA	PrimerBank
30		R	ACTCCGCTTATACTGGCTA		70		R	GCTTTTGGAGCCTTCTCTACAAT	
31	sox17	F	GTGGACCGCACGGAAATTTG	PrimerBank	71	icam1	F	ATGCCCAGACATCTGTGTCC	PrimerBank
32		R	GGAGATTCACACGGAGTCA		72		R	GGGGTCTCTATGCCCAACAA	
33	gata6	F	CTCAGTCTACGCTTCGCAT	PrimerBank	73	vtn	F	TGACCAAGAGTCATGCAAGGG	PrimerBank
34		R	GTCGAGGTCACTGAAACAGCA		74		R	ACTCAGCCGTATAGTCTGTGC	
35	foxa2	F	GGAGCAGTACTATGCAGAGC	PrimerBank	75	Dengue 2	F	CAG GTT ATG GCA CTG TCA CGA T	Johnson et al., 2005
36		R	CGTGTTCATGCCGTTTCATCC		76		R	CCA TCT GCA GCA ACA CCA TCT C	
37	hand1	F	CCATGCTCCACGAACCTTC	PrimerBank	77	probe		/5HEX/CTCTCCGAG/ZEN/AACAGGCCCTCG ACTTCAA/3IABKFQ/	Lanciotti et al., 2008
38		R	CCTGGCTCAGGACCATAG		78	zika	F	CCG CTGCCC AAC ACA AG	
39	msx1	F	CGAGAGGACCCCGTGGATGCAGAG	PrimerBank	79		R	CCA CTA ACG TTC TTT TGC AGA CAT	PrimerBank
40		R	GGCGGCATCTTCAGCTTCCAG		80		probe	-6-FAM- AGCCTACCTTGACAAGCAGTCAGACAC TCAA	

Supplementary table 1. List of qPCR primers.